Plain-English translation of NCT07239596 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called SHR-8068 combined with other anti-cancer drugs to treat advanced kidney cancer. Researchers want to see if using this medication together with existing cancer treatments is safe and helps patients live longer and feel better. About 92 people will participate in this study.
Advanced kidney cancer is difficult to treat and current options don't work well for all patients. This trial explores whether combining this new medication with established cancer treatments might give patients better results and more treatment options.
You likely qualify if…
You likely don't qualify if…
You will receive the new medication SHR-8068 combined with one of two different cancer drug combinations, depending on which study group you are assigned to. You will have regular clinic visits for blood tests, imaging scans, and physical exams to check how well the treatment is working and monitor for any side effects. The trial involves close monitoring over several months to ensure your safety and to help researchers understand whether this combination approach is helpful for patients with advanced kidney cancer.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Enrollment target
~92 participants
Started
January 2026
Primary completion
December 2030
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yuting Wang
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.